It's an appointment with excellence! The Pharmaceutical Executive APEX Awards, the only advertising awards program judged exclusively by doctors, nurses and other health care heroes, proudly announced ...

Astria Therapeutics' STAR-0215 offers revolutionary HAE treatment with superior results and minimal risks. Click here to find ...

KalVista Pharmaceuticals, Inc. , today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective immediately. Dr. Reid brings more than three decades of ...

Pharvaris N.V. ( (PHVS) ) has released its Q3 earnings. Here is a breakdown of the information Pharvaris N.V. presented to its investors.Don't ...

Penny stocks are shares of smaller or newer companies, often in their early stages of development. These companies, however, ...

CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...

Shares of biotech Intellia Therapeutics ( NTLA 5.18%) are down by around 33% over the past 30 days, amid the publication of ...

Research Triangle Park, North Carolina Tuesday, November 19, 2024, 16:00 Hrs [IST] ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on PHVS stock, giving a Buy rating yesterday.Don't Miss our Black ...

RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the Health Services ...

13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) ...